Drug Approval | May 01, 2022
USFDA approves Rinvoq as an oral treatment for ankylosing spondylitis
The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases
The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
Flagship U.S. facility will include biologic manufacturing and late stage research and clinical development of innovative cancer medicines
Pharma exports in 2021-22 sustain a positive growth despite global trade disruptions
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children
South Carolina’s largest health system adopts Philips software solutions for patient monitoring and enterprise imaging, helping to drive interoperability and data analytics, and deliver on Quadruple Aim
To extend the nationwide distribution network for the availability of its proprietary & award-winning HPod for corporates & doctors’ clinics, thereby strengthening India’s phygital wellness ecosystem
The plant is expected to start commercial operations from Q4FY24
Glenmark Pharmaceuticals won Innovation of the Year award
Subscribe To Our Newsletter & Stay Updated
